Brexucabtagene-autoleucel: Cytokine release syndrome and multiple organ dysfunction syndrome.

In a study of 23 patients with relapsed/refractory mantle cell lymphoma (R/R MCL), two patients developed cytokine release syndrome and multiple organ dysfunction syndrome after receiving treatment with brexucabtagene-autoleucel. The patients had previously received unspecified treatments and leukapheresis. One patient experienced Grade ≥3 cytokine release syndrome, while the other developed grade 5 multiple organ dysfunction syndrome on day 20 after the infusion. The specific details of the treatment, dosages, and outcomes were not provided in the article. [Extracted from the article]